Antibiotics Use and Antimicrobial Stewardship in Remote Areas—an One Health Perspective, 2nd Edition

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotics Use and Antimicrobial Stewardship".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 376

Special Issue Editor


E-Mail Website
Guest Editor
1. Consultant (Medicines Use, Safety and Policies), Barcelona, Spain
2. Former Professor at Universitat Autònoma de Barcelona, Barcelona, Spain
Interests: antimicrobial use; rational use of medicines; pharmacovigilance; drug utilization studies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first edition of the Special Issue “Antibiotics Use and Antimicrobial Stewardship in Remote Areas—an One Health Perspective” was published in 2020. It is a successful collection comprising 13 excellent papers and has encouraged us to open a second edition on the same topic.

As a continuation of the first Special Issue, this second edition aims to collect manuscript submissions that further our understanding of antimicrobial consumption and stewardship initiatives in remote places, highlighting clinical, cultural and geographical difficulties and peculiarities. Submissions taking into account the One Health perspective are especially encouraged.

Prof. Dr. Albert Figueras
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial consumption
  • antimicrobial stewardship
  • one-health
  • AWaRe classification
  • drug utilization studies
  • animal health
  • environmental health
  • human health
  • antimicrobial resistance
  • anthropological studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 513 KiB  
Article
A Nationwide Evaluation of Antibiotic Consumption in Kazakhstan from 2019 to 2023
by Yuliya Semenova, Ademi Yergaliyeva, Ainur Aimurziyeva, Almira Manatova, Anargul Kuntuganova, Larissa Makalkina, Nurgul Aldiyarova, Daniil Semenov and Lisa Lim
Antibiotics 2024, 13(12), 1123; https://doi.org/10.3390/antibiotics13121123 (registering DOI) - 23 Nov 2024
Viewed by 21
Abstract
Background/Objectives: There has been a lack of a holistic approach to evaluating antibiotic consumption in Kazakhstan over the past few years using an internationally recognized methodology. Therefore, this study aimed to provide a nationwide evaluation of antibiotic consumption in Kazakhstan during the period [...] Read more.
Background/Objectives: There has been a lack of a holistic approach to evaluating antibiotic consumption in Kazakhstan over the past few years using an internationally recognized methodology. Therefore, this study aimed to provide a nationwide evaluation of antibiotic consumption in Kazakhstan during the period 2019–2023. Methods: Defined daily doses per 1000 inhabitants per day (DIDs) were calculated for systemic antibiotics (J01 code of the Anatomical Therapeutic Chemical Classification System (ATC)) following the methodology established by the Global Antimicrobial Resistance and Use Surveillance System (GLASS-AMC). The average annual percent change (AAPC) was computed for each chemical agent, pharmacological group, and J01 in general to evaluate past trends in antibiotic consumption. Results: The consumption of J01 antibiotics ranged between 10.869 DIDs (2022) and 14.470 DIDs (2020). There was an increase in antibiotic consumption during 2020 and 2021, but the overall trend was declining, with an AAPC of −2.45%. Azithromycin was the most consumed systemic antibiotic, followed by ceftriaxone and ciprofloxacin. The consumption of “Watch” group antibiotics prevailed in Kazakhstan during the study period, with the number of people consuming the top five “Watch” group antibiotics rising from 72,578 in 2019 to 94,617 in 2023. Conclusions: The findings of this study are crucial for the reorganization of the national antimicrobial stewardship program. Full article
Show Figures

Figure 1

Back to TopTop